EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

Thomas B.L. Lam, Steven MacLennan, Peter Paul M. Willemse, Malcolm D. Mason, Karin Plass, Robert Shepherd, Ruud Baanders, Chris H. Bangma, Anders Bjartell, Alberto Bossi, Erik Briers, Alberto Briganti, Karel T. Buddingh, James W.F. Catto, Maurizio Colecchia, Brett W. Cox, Marcus G. Cumberbatch, Jeff Davies, Niall F. Davis, Maria De Santis & 49 others Paolo Dell'Oglio, André Deschamps, James F. Donaldson, Shin Egawa, Christian D. Fankhauser, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Silke Gillessen, Nikolaos Grivas, Tobias Gross, Jeremy P. Grummet, Ann M. Henry, Alexandre Ingels, Jacques Irani, Michael Lardas, Matthew Liew, Daniel W. Lin, Lisa Moris, Muhammad Imran Omar, Karl H. Pang, Catherine C. Paterson, Raphaële Renard-Penna, Maria J. Ribal, Monique J. Roobol, Morgan Rouprêt, Olivier Rouvière, Gemma Sancho Pardo, Jonathan Richenberg, Ivo G. Schoots, J. P.Michiel Sedelaar, Phillip Stricker, Derya Tilki, Susanne Vahr Lauridsen, Roderick C.N. van den Bergh, Thomas Van den Broeck, Theodorus H. van der Kwast, Henk G. van der Poel, Geert J.L.H. van Leenders, Murali Varma, Philippe D. Violette, Christopher J.D. Wallis, Thomas Wiegel, Karen Wilkinson, Fabio Zattoni, James M.O. N'Dow, Hendrik Van Poppel, Philip Cornford, Nicolas Mottet

Research output: Contribution to journalReview article

Abstract

Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.

Original languageEnglish
Pages (from-to)790-813
Number of pages24
JournalEuropean Urology
Volume76
Issue number6
Early online date3 Oct 2019
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Nuclear Medicine
Urology
Geriatrics
Prostatic Neoplasms
Consensus
Radiotherapy
Guidelines
Research
Uncertainty
Delivery of Health Care
Therapeutics
Group Processes
Practice Guidelines
Patient Selection
Research Personnel
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Clinical Trials
Prospective Studies
Biopsy

Cite this

Lam, Thomas B.L. ; MacLennan, Steven ; Willemse, Peter Paul M. ; Mason, Malcolm D. ; Plass, Karin ; Shepherd, Robert ; Baanders, Ruud ; Bangma, Chris H. ; Bjartell, Anders ; Bossi, Alberto ; Briers, Erik ; Briganti, Alberto ; Buddingh, Karel T. ; Catto, James W.F. ; Colecchia, Maurizio ; Cox, Brett W. ; Cumberbatch, Marcus G. ; Davies, Jeff ; Davis, Niall F. ; De Santis, Maria ; Dell'Oglio, Paolo ; Deschamps, André ; Donaldson, James F. ; Egawa, Shin ; Fankhauser, Christian D. ; Fanti, Stefano ; Fossati, Nicola ; Gandaglia, Giorgio ; Gillessen, Silke ; Grivas, Nikolaos ; Gross, Tobias ; Grummet, Jeremy P. ; Henry, Ann M. ; Ingels, Alexandre ; Irani, Jacques ; Lardas, Michael ; Liew, Matthew ; Lin, Daniel W. ; Moris, Lisa ; Omar, Muhammad Imran ; Pang, Karl H. ; Paterson, Catherine C. ; Renard-Penna, Raphaële ; Ribal, Maria J. ; Roobol, Monique J. ; Rouprêt, Morgan ; Rouvière, Olivier ; Sancho Pardo, Gemma ; Richenberg, Jonathan ; Schoots, Ivo G. ; Sedelaar, J. P.Michiel ; Stricker, Phillip ; Tilki, Derya ; Vahr Lauridsen, Susanne ; van den Bergh, Roderick C.N. ; Van den Broeck, Thomas ; van der Kwast, Theodorus H. ; van der Poel, Henk G. ; van Leenders, Geert J.L.H. ; Varma, Murali ; Violette, Philippe D. ; Wallis, Christopher J.D. ; Wiegel, Thomas ; Wilkinson, Karen ; Zattoni, Fabio ; N'Dow, James M.O. ; Van Poppel, Hendrik ; Cornford, Philip ; Mottet, Nicolas. / EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). In: European Urology. 2019 ; Vol. 76, No. 6. pp. 790-813.
@article{60ab0877232f4e52b2e1e7b317c22528,
title = "EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)",
abstract = "Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51{\%}); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43{\%}). Overall, 93 statements (72{\%}) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.",
keywords = "Active surveillance and monitoring, Clinical practice guidelines, Consensus group meeting, Consensus statements, Deferred treatment with curative intent, Delphi survey, Eligibility, Follow-up, Localised prostate cancer, Outcome measures, Reclassification",
author = "Lam, {Thomas B.L.} and Steven MacLennan and Willemse, {Peter Paul M.} and Mason, {Malcolm D.} and Karin Plass and Robert Shepherd and Ruud Baanders and Bangma, {Chris H.} and Anders Bjartell and Alberto Bossi and Erik Briers and Alberto Briganti and Buddingh, {Karel T.} and Catto, {James W.F.} and Maurizio Colecchia and Cox, {Brett W.} and Cumberbatch, {Marcus G.} and Jeff Davies and Davis, {Niall F.} and {De Santis}, Maria and Paolo Dell'Oglio and Andr{\'e} Deschamps and Donaldson, {James F.} and Shin Egawa and Fankhauser, {Christian D.} and Stefano Fanti and Nicola Fossati and Giorgio Gandaglia and Silke Gillessen and Nikolaos Grivas and Tobias Gross and Grummet, {Jeremy P.} and Henry, {Ann M.} and Alexandre Ingels and Jacques Irani and Michael Lardas and Matthew Liew and Lin, {Daniel W.} and Lisa Moris and Omar, {Muhammad Imran} and Pang, {Karl H.} and Paterson, {Catherine C.} and Rapha{\"e}le Renard-Penna and Ribal, {Maria J.} and Roobol, {Monique J.} and Morgan Roupr{\^e}t and Olivier Rouvi{\`e}re and {Sancho Pardo}, Gemma and Jonathan Richenberg and Schoots, {Ivo G.} and Sedelaar, {J. P.Michiel} and Phillip Stricker and Derya Tilki and {Vahr Lauridsen}, Susanne and {van den Bergh}, {Roderick C.N.} and {Van den Broeck}, Thomas and {van der Kwast}, {Theodorus H.} and {van der Poel}, {Henk G.} and {van Leenders}, {Geert J.L.H.} and Murali Varma and Violette, {Philippe D.} and Wallis, {Christopher J.D.} and Thomas Wiegel and Karen Wilkinson and Fabio Zattoni and N'Dow, {James M.O.} and {Van Poppel}, Hendrik and Philip Cornford and Nicolas Mottet",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.eururo.2019.09.020",
language = "English",
volume = "76",
pages = "790--813",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

Lam, TBL, MacLennan, S, Willemse, PPM, Mason, MD, Plass, K, Shepherd, R, Baanders, R, Bangma, CH, Bjartell, A, Bossi, A, Briers, E, Briganti, A, Buddingh, KT, Catto, JWF, Colecchia, M, Cox, BW, Cumberbatch, MG, Davies, J, Davis, NF, De Santis, M, Dell'Oglio, P, Deschamps, A, Donaldson, JF, Egawa, S, Fankhauser, CD, Fanti, S, Fossati, N, Gandaglia, G, Gillessen, S, Grivas, N, Gross, T, Grummet, JP, Henry, AM, Ingels, A, Irani, J, Lardas, M, Liew, M, Lin, DW, Moris, L, Omar, MI, Pang, KH, Paterson, CC, Renard-Penna, R, Ribal, MJ, Roobol, MJ, Rouprêt, M, Rouvière, O, Sancho Pardo, G, Richenberg, J, Schoots, IG, Sedelaar, JPM, Stricker, P, Tilki, D, Vahr Lauridsen, S, van den Bergh, RCN, Van den Broeck, T, van der Kwast, TH, van der Poel, HG, van Leenders, GJLH, Varma, M, Violette, PD, Wallis, CJD, Wiegel, T, Wilkinson, K, Zattoni, F, N'Dow, JMO, Van Poppel, H, Cornford, P & Mottet, N 2019, 'EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)', European Urology, vol. 76, no. 6, pp. 790-813. https://doi.org/10.1016/j.eururo.2019.09.020

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). / Lam, Thomas B.L.; MacLennan, Steven; Willemse, Peter Paul M.; Mason, Malcolm D.; Plass, Karin; Shepherd, Robert; Baanders, Ruud; Bangma, Chris H.; Bjartell, Anders; Bossi, Alberto; Briers, Erik; Briganti, Alberto; Buddingh, Karel T.; Catto, James W.F.; Colecchia, Maurizio; Cox, Brett W.; Cumberbatch, Marcus G.; Davies, Jeff; Davis, Niall F.; De Santis, Maria; Dell'Oglio, Paolo; Deschamps, André; Donaldson, James F.; Egawa, Shin; Fankhauser, Christian D.; Fanti, Stefano; Fossati, Nicola; Gandaglia, Giorgio; Gillessen, Silke; Grivas, Nikolaos; Gross, Tobias; Grummet, Jeremy P.; Henry, Ann M.; Ingels, Alexandre; Irani, Jacques; Lardas, Michael; Liew, Matthew; Lin, Daniel W.; Moris, Lisa; Omar, Muhammad Imran; Pang, Karl H.; Paterson, Catherine C.; Renard-Penna, Raphaële; Ribal, Maria J.; Roobol, Monique J.; Rouprêt, Morgan; Rouvière, Olivier; Sancho Pardo, Gemma; Richenberg, Jonathan; Schoots, Ivo G.; Sedelaar, J. P.Michiel; Stricker, Phillip; Tilki, Derya; Vahr Lauridsen, Susanne; van den Bergh, Roderick C.N.; Van den Broeck, Thomas; van der Kwast, Theodorus H.; van der Poel, Henk G.; van Leenders, Geert J.L.H.; Varma, Murali; Violette, Philippe D.; Wallis, Christopher J.D.; Wiegel, Thomas; Wilkinson, Karen; Zattoni, Fabio; N'Dow, James M.O.; Van Poppel, Hendrik; Cornford, Philip; Mottet, Nicolas.

In: European Urology, Vol. 76, No. 6, 01.12.2019, p. 790-813.

Research output: Contribution to journalReview article

TY - JOUR

T1 - EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

AU - Lam, Thomas B.L.

AU - MacLennan, Steven

AU - Willemse, Peter Paul M.

AU - Mason, Malcolm D.

AU - Plass, Karin

AU - Shepherd, Robert

AU - Baanders, Ruud

AU - Bangma, Chris H.

AU - Bjartell, Anders

AU - Bossi, Alberto

AU - Briers, Erik

AU - Briganti, Alberto

AU - Buddingh, Karel T.

AU - Catto, James W.F.

AU - Colecchia, Maurizio

AU - Cox, Brett W.

AU - Cumberbatch, Marcus G.

AU - Davies, Jeff

AU - Davis, Niall F.

AU - De Santis, Maria

AU - Dell'Oglio, Paolo

AU - Deschamps, André

AU - Donaldson, James F.

AU - Egawa, Shin

AU - Fankhauser, Christian D.

AU - Fanti, Stefano

AU - Fossati, Nicola

AU - Gandaglia, Giorgio

AU - Gillessen, Silke

AU - Grivas, Nikolaos

AU - Gross, Tobias

AU - Grummet, Jeremy P.

AU - Henry, Ann M.

AU - Ingels, Alexandre

AU - Irani, Jacques

AU - Lardas, Michael

AU - Liew, Matthew

AU - Lin, Daniel W.

AU - Moris, Lisa

AU - Omar, Muhammad Imran

AU - Pang, Karl H.

AU - Paterson, Catherine C.

AU - Renard-Penna, Raphaële

AU - Ribal, Maria J.

AU - Roobol, Monique J.

AU - Rouprêt, Morgan

AU - Rouvière, Olivier

AU - Sancho Pardo, Gemma

AU - Richenberg, Jonathan

AU - Schoots, Ivo G.

AU - Sedelaar, J. P.Michiel

AU - Stricker, Phillip

AU - Tilki, Derya

AU - Vahr Lauridsen, Susanne

AU - van den Bergh, Roderick C.N.

AU - Van den Broeck, Thomas

AU - van der Kwast, Theodorus H.

AU - van der Poel, Henk G.

AU - van Leenders, Geert J.L.H.

AU - Varma, Murali

AU - Violette, Philippe D.

AU - Wallis, Christopher J.D.

AU - Wiegel, Thomas

AU - Wilkinson, Karen

AU - Zattoni, Fabio

AU - N'Dow, James M.O.

AU - Van Poppel, Hendrik

AU - Cornford, Philip

AU - Mottet, Nicolas

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.

AB - Background: There is uncertainty in deferred active treatment (DAT) programmes, regarding patient selection, follow-up and monitoring, reclassification, and which outcome measures should be prioritised. Objective: To develop consensus statements for all domains of DAT. Design, setting, and participants: A protocol-driven, three phase study was undertaken by the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Association of Urology Section of Urological Research (ESUR)-International Society of Geriatric Oncology (SIOG) Prostate Cancer Guideline Panel in conjunction with partner organisations, including the following: (1) a systematic review to describe heterogeneity across all domains; (2) a two-round Delphi survey involving a large, international panel of stakeholders, including healthcare practitioners (HCPs) and patients; and (3) a consensus group meeting attended by stakeholder group representatives. Robust methods regarding what constituted the consensus were strictly followed. Results and limitations: A total of 109 HCPs and 16 patients completed both survey rounds. Of 129 statements in the survey, consensus was achieved in 66 (51%); the rest of the statements were discussed and voted on in the consensus meeting by 32 HCPs and three patients, where consensus was achieved in additional 27 statements (43%). Overall, 93 statements (72%) achieved consensus in the project. Some uncertainties remained regarding clinically important thresholds for disease extent on biopsy in low-risk disease, and the role of multiparametric magnetic resonance imaging in determining disease stage and aggressiveness as a criterion for inclusion and exclusion. Conclusions: Consensus statements and the findings are expected to guide and inform routine clinical practice and research, until higher levels of evidence emerge through prospective comparative studies and clinical trials. Patient summary: We undertook a project aimed at standardising the elements of practice in active surveillance programmes for early localised prostate cancer because currently there is great variation and uncertainty regarding how best to conduct them. The project involved large numbers of healthcare practitioners and patients using a survey and face-to-face meeting, in order to achieve agreement (ie, consensus) regarding best practice, which will provide guidance to clinicians and researchers.

KW - Active surveillance and monitoring

KW - Clinical practice guidelines

KW - Consensus group meeting

KW - Consensus statements

KW - Deferred treatment with curative intent

KW - Delphi survey

KW - Eligibility

KW - Follow-up

KW - Localised prostate cancer

KW - Outcome measures

KW - Reclassification

UR - http://www.scopus.com/inward/record.url?scp=85072774547&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.09.020

DO - 10.1016/j.eururo.2019.09.020

M3 - Review article

VL - 76

SP - 790

EP - 813

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -